重症肌无力与新型冠状病毒肺炎：临床特征与转归
Myasthenia Gravis and COVID-19: Clinical Characteristics and Outcomes.
作者信息
Camelo-Filho Antonio E, Silva André M S, Estephan Eduardo P, Zambon Antônio A, Mendonça Rodrigo H, Souza Paulo V S, Pinto Wladimir B V R, Oliveira Acary S B, Dangoni-Filho Iron, Pouza Ana F P, Valerio Berenice C O, Zanoteli Edmar
机构信息
Department of Neurology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
Department of Neurology, Faculdade de Medicina Santa Marcelina, São Paulo, Brazil.
出版信息
Front Neurol. 2020 Sep 11;11:1053. doi: 10.3389/fneur.2020.01053. eCollection 2020.
Abstract
Myasthenia gravis (MG), an autoimmune neuromuscular disorder, may be a risk factor for severe COVID-19. We conducted an observational retrospective study with 15 consecutive adult MG patients admitted with COVID-19 at four hospitals in São Paulo, Brazil. Most patients with MG hospitalized for COVID-19 had severe courses of the disease: 87% were admitted in the intensive care unit, 73% needed mechanical ventilation, and 30% died. Immunoglobulin use and the plasma exchange procedure were safe. Immunosuppressive therapy seems to be associated with better outcomes, as it might play a protective role.
摘要
重症肌无力（MG）是一种自身免疫性神经肌肉疾病，可能是重症 COVID-19 的一个危险因素。我们在巴西圣保罗的四家医院对 15 例连续收治的成年 COVID-19 合并 MG 患者进行了一项观察性回顾性研究。大多数因 COVID-19 住院的 MG 患者病情严重：87% 入住重症监护病房，73% 需要机械通气，30% 死亡。使用免疫球蛋白和进行血浆置换术是安全的。免疫抑制治疗似乎与更好的预后相关，因为它可能起到保护作用。
相似文献
1
Myasthenia Gravis and COVID-19: Clinical Characteristics and Outcomes.重症肌无力与新型冠状病毒肺炎：临床特征与转归
Front Neurol. 2020 Sep 11;11:1053. doi: 10.3389/fneur.2020.01053. eCollection 2020.
2
Case series of COVID-19 in patients with myasthenia gravis: a single institution experience.COVID-19 合并重症肌无力患者的病例系列：单中心经验。
Acta Neurol Belg. 2021 Aug;121(4):1039-1044. doi: 10.1007/s13760-021-01662-w. Epub 2021 Apr 1.
3
Impact of Coronavirus Disease 2019 in a French Cohort of Myasthenia Gravis.新型冠状病毒肺炎对法国重症肌无力队列的影响。
Neurology. 2021 Apr 20;96(16):e2109-e2120. doi: 10.1212/WNL.0000000000011669. Epub 2021 Feb 10.
4
Clinical features and outcomes of patients with myasthenia gravis affected by COVID-19: A single-center study.COVID-19 影响下的重症肌无力患者的临床特征和结局：一项单中心研究。
Clin Neurol Neurosurg. 2022 Nov;222:107441. doi: 10.1016/j.clineuro.2022.107441. Epub 2022 Sep 13.
5
COVID-19 infection in myasthenia gravis: Clinical course and outcomes.COVID-19 感染与重症肌无力：临床过程和结局。
Muscle Nerve. 2023 Aug;68(2):171-175. doi: 10.1002/mus.27919. Epub 2023 Jun 16.
6
Intravenous immunoglobulin for myasthenia gravis.静脉注射免疫球蛋白治疗重症肌无力
Cochrane Database Syst Rev. 2003(2):CD002277. doi: 10.1002/14651858.CD002277.
7
Intravenous immunoglobulin for myasthenia gravis.静脉注射免疫球蛋白治疗重症肌无力
Cochrane Database Syst Rev. 2006 Apr 19(2):CD002277. doi: 10.1002/14651858.CD002277.pub2.
8
Intravenous immunoglobulin for myasthenia gravis.静脉注射免疫球蛋白治疗重症肌无力
Cochrane Database Syst Rev. 2008 Jan 23(1):CD002277. doi: 10.1002/14651858.CD002277.pub3.
9
Myasthenic Crisis.重症肌无力危象
Curr Treat Options Neurol. 2004 Jan;6(1):3-15. doi: 10.1007/s11940-004-0034-3.
10
Myasthenia and the neuromuscular junction.重症肌无力与神经肌肉接头
Curr Opin Neurol. 2012 Oct;25(5):523-9. doi: 10.1097/WCO.0b013e3283572588.
引用本文的文献
1
Impact of SARS-CoV-2 infection on patients with myasthenia gravis: a retrospective study in a Chinese population.新型冠状病毒2019感染对重症肌无力患者的影响：一项中国人群的回顾性研究
Front Neurol. 2024 Dec 11;15:1482932. doi: 10.3389/fneur.2024.1482932. eCollection 2024.
2
Evaluation of Clinical Effects of COVID-19 Infection and Vaccines on Myasthenia Gravis.新型冠状病毒肺炎感染及疫苗对重症肌无力临床影响的评估
Noro Psikiyatr Ars. 2024 Aug 19;67(3):213-220. doi: 10.29399/npa.28418. eCollection 2024.
3
Clinical features of COVID-19 infection in patients with myasthenia gravis: a real-world retrospective study.新冠病毒感染合并重症肌无力患者的临床特征：一项真实世界的回顾性研究。
Front Public Health. 2024 Aug 27;12:1421211. doi: 10.3389/fpubh.2024.1421211. eCollection 2024.
4
Myasthenia Gravis and COVID-19: A Systematic Review and Meta-analysis.重症肌无力与2019冠状病毒病：一项系统评价与荟萃分析
Basic Clin Neurosci. 2024 Mar-Apr;15(2):175-184. doi: 10.32598/bcn.2023.4360.5. Epub 2024 Mar 1.
5
The Neurological Implications of COVID-19: A Comprehensive Narrative Review.新型冠状病毒肺炎的神经学影响：一项全面的叙述性综述
Cureus. 2024 May 15;16(5):e60376. doi: 10.7759/cureus.60376. eCollection 2024 May.
6
Impact of COVID-19 pandemic on the incidence and severity of myasthenia gravis in Korea: using National Health Insurance Service database.新型冠状病毒肺炎大流行对韩国重症肌无力发病率和严重程度的影响：利用国民健康保险服务数据库
Front Neurol. 2024 May 6;15:1374370. doi: 10.3389/fneur.2024.1374370. eCollection 2024.
7
Impact of COVID-19 Infection and Its Association With Previous Vaccination in Patients With Myasthenia Gravis in Korea: A Multicenter Retrospective Study.韩国重症肌无力患者 COVID-19 感染及其与既往疫苗接种的关系：一项多中心回顾性研究。
J Korean Med Sci. 2024 May 13;39(18):e150. doi: 10.3346/jkms.2024.39.e150.
8
COVID-19 in patients with myasthenia gravis: a single-center retrospective study in China.中国单中心回顾性研究：COVID-19 合并重症肌无力患者。
Neurol Sci. 2024 Jul;45(7):2969-2976. doi: 10.1007/s10072-024-07518-4. Epub 2024 Apr 23.
9
SARS-CoV-2 and Brain Health: New Challenges in the Era of the Pandemic.严重急性呼吸综合征冠状病毒2与脑健康：大流行时代的新挑战
Microorganisms. 2023 Oct 8;11(10):2511. doi: 10.3390/microorganisms11102511.
10
Therapeutic and prognostic features in myasthenia gravis patients followed in a tertiary neuromuscular diseases center in Turkey.在土耳其一家三级神经肌肉疾病中心随访的重症肌无力患者的治疗和预后特征。
Front Neurol. 2023 Aug 3;14:1176636. doi: 10.3389/fneur.2023.1176636. eCollection 2023.
本文引用的文献
1
COVID-19 in Refractory Myasthenia Gravis- A Case Report of Successful Outcome.COVID-19 合并难治性重症肌无力：成功治疗 1 例报告
J Neuromuscul Dis. 2020;7(3):361-364. doi: 10.3233/JND-200520.
2
Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry.新型冠状病毒肺炎住院患者的神经系统表现：ALBACOVID注册研究
Neurology. 2020 Aug 25;95(8):e1060-e1070. doi: 10.1212/WNL.0000000000009937. Epub 2020 Jun 1.
3
A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19.微妙的平衡：免疫抑制与免疫疗法在多发性硬化合并 COVID-19 患者中的应用。
Mult Scler Relat Disord. 2020 Jul;42:102182. doi: 10.1016/j.msard.2020.102182. Epub 2020 May 8.
4
Myasthenic crisis in COVID-19.新冠病毒相关性肌无力危象。
J Neurol Sci. 2020 Jul 15;414:116888. doi: 10.1016/j.jns.2020.116888. Epub 2020 May 6.
5
COVID-19 in patients with myasthenia gravis.COVID-19 与重症肌无力。
Muscle Nerve. 2020 Aug;62(2):254-258. doi: 10.1002/mus.26918. Epub 2020 May 22.
6
Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.在纽约市地区，5700 名因 COVID-19 住院的患者的特征、合并症和结局。
JAMA. 2020 May 26;323(20):2052-2059. doi: 10.1001/jama.2020.6775.
7
COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?奥瑞珠单抗治疗多发性硬化症患者合并 COVID-19：免疫抑制是否具有保护作用？
Mult Scler Relat Disord. 2020 Jul;42:102120. doi: 10.1016/j.msard.2020.102120. Epub 2020 Apr 15.
8
SARS-CoV-2 and viral sepsis: observations and hypotheses.SARS-CoV-2 与病毒败血症：观察与假说。
Lancet. 2020 May 9;395(10235):1517-1520. doi: 10.1016/S0140-6736(20)30920-X. Epub 2020 Apr 17.
9
COVID-19 and neuromuscular disorders.新型冠状病毒肺炎与神经肌肉疾病。
Neurology. 2020 Jun 2;94(22):959-969. doi: 10.1212/WNL.0000000000009566. Epub 2020 Apr 13.
10
Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China.中国武汉住院的 2019 年冠状病毒病患者的神经系统表现。
JAMA Neurol. 2020 Jun 1;77(6):683-690. doi: 10.1001/jamaneurol.2020.1127.
Zotero 插件